Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

A risankizumab super responder profile identified by long‐term real‐life observation‐IL PSO (ITALIAN LANDSCAPE PSORIASIS)
Luigi Gargiulo, Luciano Ibba, Piergiorgio Malagoli, et al.
Journal of the European Academy of Dermatology and Venereology (2023) Vol. 38, Iss. 1
Open Access | Times Cited: 10

Showing 10 citing articles:

Drug survival of IL-12/23, IL-17 and IL-23 inhibitors for moderate-to-severe plaque psoriasis: a retrospective multicenter real-world experience on 5932 treatment courses – IL PSO (Italian landscape psoriasis)
Luigi Gargiulo, Luciano Ibba, Piergiorgio Malagoli, et al.
Frontiers in Immunology (2024) Vol. 14
Open Access | Times Cited: 22
Bimekizumab for the Treatment of Plaque Psoriasis With Involvement of Genitalia: A 16-Week Multicenter Real-World Experience—IL PSO (Italian Landscape Psoriasis)
Diego Orsini, Piergiorgio Malagoli, Anna Balato, et al.
Dermatology Practical & Conceptual (2024) Vol. 14, Iss. 2, pp. e2024052-e2024052
Open Access | Times Cited: 17
A Novel Fault Diagnosis Method for a Power Transformer Based on Multi-Scale Approximate Entropy and Optimized Convolutional Networks
Haikun Shang, Zhidong Liu, Yanlei Wei, et al.
Entropy (2024) Vol. 26, Iss. 3, pp. 186-186
Open Access | Times Cited: 10
The Role of Interleukin 23/17 Axis in Psoriasis Management: A Comprehensive Review of Clinical Trials
Luca Potestio, Fabrizio Martora, Giuseppe Lauletta, et al.
Clinical Cosmetic and Investigational Dermatology (2024) Vol. Volume 17, pp. 829-842
Open Access | Times Cited: 10
Effectiveness, Tolerability, and Drug Survival of Risankizumab in a Real-World Setting: A Three-Year Retrospective Multicenter Study—IL PSO (ITALIAN LANDSCAPE PSORIASIS)
Luigi Gargiulo, Luciano Ibba, Piergiorgio Malagoli, et al.
Journal of Clinical Medicine (2024) Vol. 13, Iss. 2, pp. 495-495
Open Access | Times Cited: 8
Long‐term real‐world effectiveness of deucravacitinib in psoriasis: A 52‐week prospective study stratified by prior apremilast or biologic therapy
Teppei Hagino, Hidehisa Saeki, Eita Fujimoto, et al.
The Journal of Dermatology (2025)
Open Access
Optimizing Tildrakizumab Dosing in Psoriasis: A 52-Week Multicenter Retrospective Study Comparing 100 mg and 200 mg—IL PSO (Italian Landscape Psoriasis)
Mario Valenti, Luciano Ibba, S. Di Giulio, et al.
Dermatology and Therapy (2025)
Open Access
Long-term effectiveness and safety of risankizumab in patients with moderate-to-severe psoriasis with and without cardiometabolic comorbidities: a single-center retrospective study
Luciano Ibba, S. Di Giulio, Luigi Gargiulo, et al.
Journal of Dermatological Treatment (2024) Vol. 35, Iss. 1
Open Access | Times Cited: 2
Effectiveness and safety of risankizumab in VEry severe plaque psoriasis: a real-life retrospective study (VESPA-Study)
Diego Orsini, Chiara Assorgi, Claudio Bonifati, et al.
Journal of Dermatological Treatment (2024) Vol. 35, Iss. 1
Open Access | Times Cited: 1
Risankizumab for severe psoriasis: a case of successful retreatment without induction after 15 months of discontinuation
Edoardo Mortato, Silvia Baratta, Riccardo Viola, et al.
Italian Journal of Dermatology and Venereology (2024) Vol. 159, Iss. 2
Closed Access
Page 1

Scroll to top